The Effects of Screw Configuration and Polymeric Carriers on Hot-Melt Extruded Taste-Masked Formulations Incorporated into Orally Disintegrating Tablets

被引:41
作者
Morott, Joseph T. [1 ]
Pimparade, Manjeet [1 ]
Park, Jun-Bom [1 ]
Worley, Chelsea P. [3 ]
Majumdar, Soumyajit [1 ]
Lian, Zhuoyang
Pinto, Elanor
Bi, Yunxia
Durig, Thomas
Repka, Michael A. [1 ,2 ]
机构
[1] Univ Mississippi, Dept Pharmaceut Drug Delivery, University, MS USA
[2] Univ Mississippi, Sch Pharm, Pii Ctr Pharmaceut Technol, University, MS USA
[3] Univ Mississippi, Dept Chem Engn, University, MS USA
关键词
Hot Melt Extrusion; Taste Masking; Crystalline Solid Dispersion; Bitter API; Disintegrating Tablets; Chemical Imaging; Screw Configuration;
D O I
10.1002/jps.24262
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The primary aim of this research was to produce successfully taste masked formulations of Sildenafil Citrate (SC) using hot-melt extrusion (HME) technology. Multiple screw configurations and polymeric carriers were evaluated for their effects on taste masking efficiency, which was assessed by both E-tongue analysis and in vitro dissolution in simulated salivary fluid (SSF, pH 6.8 artificial saliva). The screw configurations were further assessed for their effects on the morphology of the API using PXRD, FT-IR and mid-infrared chemical imaging. It was determined that the screw configuration had a profound effect on the taste masking efficiency of the formulations as a result of altering the physical state of the API. Selected extruded formulations using ethylcellulose (EC) with a pore former were further formulated into orally disintegrating tablets (ODTs), which were optimized by varying the grade and percentage of the superdisintegrant used. An optimized disintegration time of approximately 8 seconds was achieved. The final ODT formulation exhibited excellent taste masking properties with over 85% drug release in gastric media as well as physical tablet properties. Interestingly, friability, which tends to be a common concern when formulating ODTs, was well within the acceptable limits (<1%) for common tablets. (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:124-134, 2015
引用
收藏
页码:124 / 134
页数:11
相关论文
共 23 条
  • [1] [Anonymous], 1998, VIAGR SILD CITR TABL
  • [2] [Anonymous], 2005, REV SILD CITR TABL P
  • [3] Ayenew Zelalem, 2009, Recent Pat Drug Deliv Formul, V3, P26
  • [4] Current perspectives in dissolution testing of conventional and novel dosage forms
    Azarmi, Shirzad
    Roa, Wilson
    Lobenberg, Raimar
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 328 (01) : 12 - 21
  • [5] Banker G.S., 2002, Modern Pharmaceutics, V4th, P674
  • [6] RISK-FACTORS IN GERIATRIC DRUG PRESCRIBING - A PRACTICAL GUIDE TO AVOIDING PROBLEMS
    BEERS, MH
    OUSLANDER, JG
    [J]. DRUGS, 1989, 37 (01) : 105 - 112
  • [7] Pharmaceutical applications of hot-melt extrusion: Part I
    Crowley, Michael M.
    Zhang, Feng
    Repka, Michael A.
    Thumma, Sridhar
    Upadhye, Sampada B.
    Battu, Sunil Kumar
    McGinity, James W.
    Martin, Charles
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (09) : 909 - 926
  • [8] Egilius LH, 2004, CNS DRUGS, V18, P1133
  • [9] FDA, 2014, ALPH LIST SCOGS SUBS
  • [10] The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction
    Gupta, M
    Kovar, A
    Meibohm, B
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09) : 987 - 1003